USPTO serial 88751602
IMMUVANCE
Reviewed by CopyMark Law Group
Status 605
- Filing date
- Status date
- Registration date
- —
- Examiner
- OWCZARSKI, KAREN
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with IMMUVANCE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Vancouver, WA
Vancouver, WA
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jared M. Barrett
Jared M. Barrett SEED IP LAW GROUP LLP701 FIFTH AVENUE, SUITE 5400SEATTLE, WA 98104UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | therapeutic preparations, namely, antibodies for use in targeting the CCR5 cell receptor; therapeutic preparations for the treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; therapeutic preparations for the prevention of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19 | ABANDONED | — |
| 042 | scientific research consulting services in the field of immunology; scientific research consulting services in the field of antibodies for use in targeting the CCR5 cell receptor; scientific research consulting services in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; medical research services; medical research services in the field of antibodies for use in targeting the CCR5 cell receptor; medical research services in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; all of the foregoing excluding medical research and scientific research consulting services directed to adjuvants for vaccines and molecular genetics and genomics testing and reporting | ABANDONED | — |
| 044 | providing a website featuring medical information; providing a website featuring information in the field of antibodies for use in targeting the CCR5 cell receptor; providing health and medical information, namely, providing a website featuring information in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; all of the forgoing excluding information directed to adjuvants for vaccines and molecular genetics and genomics testing and reporting | ABANDONED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 10, 2022 | MAB5 | ABANDONMENT NOTICE E-MAILED - AFTER PUBLICATION | — |
| Jun 10, 2022 | ABN5 | ABANDONMENT - AFTER PUBLICATION | — |
| Jun 9, 2022 | EXAR | TEAS EXPRESS ABANDONMENT RECEIVED | — |
| Mar 24, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Mar 22, 2022 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Mar 22, 2022 | EXT3 | SOU EXTENSION 3 FILED | — |
| Mar 22, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Aug 14, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 12, 2021 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Aug 12, 2021 | EXT2 | SOU EXTENSION 2 FILED | — |
| Aug 12, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 19, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Mar 17, 2021 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Mar 17, 2021 | EXT1 | SOU EXTENSION 1 FILED | — |
| Mar 17, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 22, 2020 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jul 28, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 28, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 8, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jun 24, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 24, 2020 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jun 24, 2020 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jun 24, 2020 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jun 24, 2020 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jun 23, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 22, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 22, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 27, 2020 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 27, 2020 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 27, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 26, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 13, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 11, 2020 | NWAP | NEW APPLICATION ENTERED | — |